共 50 条
- [33] Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial LANCET NEUROLOGY, 2021, 20 (04): : 284 - 293
- [39] Reply to F. Muntoni et al.: "In response to PR Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy JOURNAL OF NEUROMUSCULAR DISEASES, 2023, 10 (06) : 1155 - 1157